Citing unnamed sources, the Globes paper said Stryker is looking at a purchase price of $20 million to $30 million for ActiViews.
Wakefield, Mass.-based ActiViews landed FDA clearance for the lung device in July 2011. The company won FDA clearance for its needle guidance system for liver interventions earlier this year. Chinese regulatory authorities granted their approval for both the lung and liver indications in May 2012.
The co-founders of ActiViews, CEO Yuval Zuk and president & CTO Pinchas Gilboa, have a strong track record of creating companies that are later snapped up by large medtech players. Zuk founded Odin Medical Technologies, acquired for $9 million by Medtronic (NYSE:MDT) in 2006. Gilboa started superDimension Ltd., which Covidien (NYSE:COV) acquired for $300 million last year.
Stryker has been on an acquisitions tear with CEO Kevin Lobo affirming its appetite for dealmaking. Most recently, it agreed to pony up $1.65 billion for Mako Surgical. The company agreed to pay $764 million in January for Trauson, a Chinese medical device company that makes spinal and trauma care products. In October 2012, the Kalamazoo, Mich.-based orthopedics giant agreed to pay up to $135 million to acquire Israeli stent maker Surpass Medical. Stryker paid $316 million for Orthovita in 2011.
The scale of any acquisitions might be lower than the blockbuster Mako deal, however. Yesterday, Stryker upped its estimate of the cost of the recall of its Rejuvenate and ABG II hip implants to a top end of more than $1 billion.